Edition:
United Kingdom

Cancer Genetics Inc (CGIX.OQ)

CGIX.OQ on NASDAQ Stock Exchange Capital Market

1.26USD
21 Sep 2018
Change (% chg)

$0.12 (+11.01%)
Prev Close
$1.13
Open
$1.16
Day's High
$1.29
Day's Low
$1.16
Volume
175,966
Avg. Vol
18,764
52-wk High
$3.45
52-wk Low
$0.83

Latest Key Developments (Source: Significant Developments)

Cancer Genetics’ Unique Tissue Of Origin Test (Too®) Receives Special FDA 510(K) Clearance
Monday, 16 Apr 2018 

April 16 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS’ UNIQUE TISSUE OF ORIGIN TEST (TOO®) RECEIVES SPECIAL FDA 510(K) CLEARANCE.CANCER GENETICS’ UNIQUE TISSUE OF ORIGIN TEST (TOO®) RECEIVES SPECIAL FDA 510(K) CLEARANCE.  Full Article

Cancer Genetics Receives Non-Dilutive Funding Of $1.1 Mln
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS RECEIVES NON-DILUTIVE FUNDING OF $1.1 MILLION THROUGH NEW JERSEY TECHNOLOGY BUSINESS TAX CERTIFICATE TRANSFER (NOL) PROGRAM.CANCER GENETICS INC - ‍RECEIVED $1.1 MILLION IN NET CASH PROCEEDS FROM TRANSFER OF TAX CREDITS.  Full Article

Stonepine Capital Management Reports 5 Percent Passive Stake In Cancer Genetics
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Stonepine Capital Management::STONEPINE CAPITAL MANAGEMENT REPORTS 5 PERCENT PASSIVE STAKE IN CANCER GENETICS INC AS ON DEC 12 - SEC FILING.  Full Article

Cancer Genetics Receives New York State Approval For Oncomine Dx Target Test
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS RECEIVES NEW YORK STATE APPROVAL FOR FDA-APPROVED ONCOMINE DX TARGET TEST BY THERMO FISHER SCIENTIFIC.  Full Article

Cancer Genetics Q3 loss per share $0.15
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cancer Genetics Inc :Cancer genetics reports record third quarter 2017 revenue and 134% increase in contracted bookings from major biotech and pharmaceutical companies.Q3 loss per share $0.15.Q3 revenue $8.0 million versus i/b/e/s view $7.9 million.Q3 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Cancer genetics inc - ‍integration of vivopharm acquisition is on-track and will deliver a full quarter of results and additional revenue in q4 of 2017​.  Full Article

BRIEF-Cancer Genetics Says Appointed John Roberts As CEO And President

* CANCER GENETICS SAYS ON APRIL 30, BOARD APPOINTED JOHN ROBERTS AS COMPANY'S CEO AND PRESIDENT - SEC FILING Source: (https://bit.ly/2w2ruOW) Further company coverage: